FDA Approval for New Cardiac Devices in Advanced Diagnostic Imaging
By MedImaging International staff writers Posted on 26 Oct 2016 |
Image: The OptiVol fluid status monitoring for monitor heart failure in patients with a Medtronic ICD (Photo courtesy of Medtronic).
The US Food and Drug Administration (FDA) has approved a suite of cardiac rhythm and heart failure devices, including leads, for use in 3T and 1.5T Magnetic Resonance Imaging (MRI) machines.
The FDA approval will allow patients fitted with MR-conditional pacemakers, Cardiac Resynchronization Therapy-Defibrillators (CRT-Ds), Implantable Cardioverter-Defibrillators (ICDs), and their leads, to undergo MRI scans.
The approved devices are the Medtronic (Dublin, Ireland) Advisa MRI, and Micra Transcatheter Pacemakers, Amplia MRI and Compia MRI CRT-Ds, Evera MRI and Visia AF MRI DF-1 and DF4 ICDs, Reveal LINQ insertable cardiac monitor, SureScan pacing, defibrillation and left-heart leads. Medtronic is a large medical technology, services and solutions company and manufactures a range of devices for interventional, and surgical treatment of cardiac arrhythmias, and cardiovascular disease.
Yair Safriel, MD, neuroradiologist, CMO, Pharmascan Clinical Trials, and University of South Florida, said, "While 1.5T scanners still comprise the majority of installations, 3T scanners are expected to comprise more than half of new units - with some centers having only 3T scanners - since they offer faster scans and higher resolution images. Approval for MRI conditional scanning at both 1.5 and 3T allows patients to have improved access to MRI at a time and place most appropriate for their care. And with 3T scanning, physicians and radiologists gain a clearer look into soft tissues, particularly critical when diagnosing serious conditions, often involving the brain and spine."
Related Links:
Medtronic
The FDA approval will allow patients fitted with MR-conditional pacemakers, Cardiac Resynchronization Therapy-Defibrillators (CRT-Ds), Implantable Cardioverter-Defibrillators (ICDs), and their leads, to undergo MRI scans.
The approved devices are the Medtronic (Dublin, Ireland) Advisa MRI, and Micra Transcatheter Pacemakers, Amplia MRI and Compia MRI CRT-Ds, Evera MRI and Visia AF MRI DF-1 and DF4 ICDs, Reveal LINQ insertable cardiac monitor, SureScan pacing, defibrillation and left-heart leads. Medtronic is a large medical technology, services and solutions company and manufactures a range of devices for interventional, and surgical treatment of cardiac arrhythmias, and cardiovascular disease.
Yair Safriel, MD, neuroradiologist, CMO, Pharmascan Clinical Trials, and University of South Florida, said, "While 1.5T scanners still comprise the majority of installations, 3T scanners are expected to comprise more than half of new units - with some centers having only 3T scanners - since they offer faster scans and higher resolution images. Approval for MRI conditional scanning at both 1.5 and 3T allows patients to have improved access to MRI at a time and place most appropriate for their care. And with 3T scanning, physicians and radiologists gain a clearer look into soft tissues, particularly critical when diagnosing serious conditions, often involving the brain and spine."
Related Links:
Medtronic
Latest MRI News
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
- AI-Based MRI Tool Outperforms Current Brain Tumor Diagnosis Methods
- DW-MRI Lights up Small Ovarian Lesions like Light Bulbs